Af­ter two rounds of mixed da­ta, Eli Lil­ly im­press­es an­a­lysts with new Covid-19 an­ti­body re­sults. And ex­ecs want an EUA now

Eli Lil­ly has more da­ta from their Covid-19 neu­tral­iz­ing an­ti­bod­ies — da­ta, they say, should war­rant an FDA OK.

The Big Phar­ma said Wednes­day that a cock­tail of two mon­o­clon­al an­ti­bod­ies looked safe and re­duced vi­ral load in Covid-19 pa­tients. It al­so al­le­vi­at­ed symp­toms and re­duced ER vis­its and hos­pi­tal­iza­tion rate com­pared to place­bo, ap­pear­ing over­all to pro­vide bet­ter re­sults than a sin­gle Lil­ly an­ti­body showed in Sep­tem­ber and to com­pare fa­vor­ably with the Re­gen­eron an­ti­body cock­tail that Pres­i­dent Trump re­ceived last week.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA